Hypoactive Sexual Desire Disorder (HSDD) is a serious condition experienced by about ten percent of pre-menopausal women, yet it has taken seven years for this drug, Flibanserin (Addyi), to get the green-light.
National Organization for Women Welcomes FDA Decision on Women’s HSDD Treatment
Released on August 19, 2015